Healthcare Services

Global Coagulation Factor Deficiency Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

March 31, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Coagulation Factor Deficiency Market Projected To Become By 2030 Based On Its 2026 Valuation?

The coagulation factor deficiency market size has experienced robust growth in recent years. It is projected to expand from $4.93 billion in 2025 to $5.3 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. This historical growth can be attributed to several factors including improved diagnosis of bleeding disorders, the increased availability of plasma-derived therapies, the expansion of hemophilia treatment centers, a rise in patient awareness programs, and the development of specialty healthcare services.

The coagulation factor deficiency market is set for substantial growth over the next few years. It is projected to expand to $7.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This anticipated growth is driven by progress in gene therapy development, an increasing demand for tailored treatments for bleeding disorders, the expansion of home care treatment models, a heightened focus on reducing the frequency of treatments, and rising investments in rare disease therapeutics. Prominent trends expected in this period include the wider adoption of recombinant coagulation factors, the growing application of gene therapy-based treatments, a stronger preference for prophylactic treatment regimens, the spread of home-based infusion therapies, and an intensified focus on long-acting factor products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21152&type=smp

Which Market Drivers Are Supporting The Expansion Of The Coagulation Factor Deficiency Market?

The anticipated expansion of the coagulation factor deficiency market is driven by the rising occurrence of blood-related conditions. These disorders encompass various conditions impacting the creation, role, or makeup of blood cells, platelets, or plasma, resulting in issues like anemia, coagulation difficulties, or immune system weaknesses. The escalation in blood-related disorders can be attributed to several factors including an aging global population, inherited tendencies, enhanced public understanding, environmental influences, shifts in lifestyle, the increasing prevalence of chronic illnesses, and improved diagnostic techniques facilitating prompt identification. Coagulation factor deficiency plays a crucial role in managing blood-related disorders by supplying vital clotting factors necessary to prevent or regulate excessive bleeding in conditions such as hemophilia, where the body’s inherent capacity to form blood clots is compromised. For example, data from September 2024 from the Leukemia and Lymphoma Society, a US-based professional organization company, indicates that Every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2024, an estimated 187,740 individuals face these cancers, which represents 9.4% of the expected 2,001,140 new cancer cases in the US. Furthermore, as of May 2024, information from the National Health Service (NHS) England, a UK-based government-funded healthcare system, reveals that in England, approximately 17,000 people are living with sickle cell disease, an inherited blood disorder, and around 250 new cases are diagnosed annually. Consequently, the rising prevalence of blood-related disorders is fueling the expansion of the coagulation factor deficiency market.

What Segment Groups Are Identified Within The Coagulation Factor Deficiency Market?

The coagulation factor deficiency market covered in this report is segmented –

1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-Derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types

2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types

3) By End Users: Hospitals, Clinics, Home Care, Other End Users

Subsegments:

1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa

2) By Plasma-Derived Coagulation Factor Concentrates: Plasma-Derived Factor VIII, Plasma-Derived Factor IX, Plasma-Derived Factor VII

3) By Biologics: Monoclonal Antibodies, Gene Therapy Products

4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin

5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)

How Are Trends Shaping The Direction Of The Coagulation Factor Deficiency Market?

Leading companies in the coagulation factor deficiency market are concentrating on developing innovative treatments, such as one-time gene therapy, to offer long-term or potentially curative solutions for patients suffering from bleeding disorders like hemophilia, thereby reducing the need for continuous infusions of clotting factors. This one-time gene therapy is a medical intervention that involves introducing or altering genetic material within a patient’s cells to treat or cure a disease, with the goal of providing lasting or permanent therapeutic effects after just a single administration. For example, in April 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who are currently receiving factor IX (FIX) prophylaxis therapy. This specific therapy is a one-time adeno-associated virus (AAV)-based gene therapy designed to introduce a functional copy of the FIX gene, which encodes a high-activity FIX variant, into the transduced cells. As a result, patients with hemophilia B can produce FIX themselves through this single treatment, eliminating the necessity for frequent FIX infusions.

Which Companies Hold Significant Positions In The Coagulation Factor Deficiency Market?

Major companies operating in the coagulation factor deficiency market are Pfizer Inc., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, BioMarin Pharmaceutical Inc., uniQure, Prothya Biosolutions, Bio Products Laboratory Ltd, Green Cross Corporation, Freeline Therapeutics, Aptevo Therapeutics, Hema Biologics LLC, Generation Bio Co, Intellia Therapeutics Inc.

Read the full coagulation factor deficiency market report here:

https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report

How Is The Coagulation Factor Deficiency Market Distributed Across Key Geographic Regions?

North America was the largest region in the coagulation factor deficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Coagulation Factor Deficiency Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21152&type=smp

Browse Through More Reports Similar to the Global Coagulation Factor Deficiency Market 2026, By The Business Research Company

Polyclonal Antibodies Global Market Report

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Next Generation Antibody Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Monoclonal Antibodies Global Market Report

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795